BMO Capital Markets Forecasts Strong Price Appreciation for Replimune Group (NASDAQ:REPL) Stock

Replimune Group (NASDAQ:REPL) had its target price boosted by BMO Capital Markets from $18.00 to $27.00 in a report released on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. BMO Capital Markets’ target price suggests a potential upside of 104.58% from the company’s current price.

A number of other analysts have also recently weighed in on REPL. HC Wainwright raised their price objective on shares of Replimune Group from $17.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday. Jefferies Financial Group raised their target price on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, December 4th. Finally, JPMorgan Chase & Co. raised their target price on shares of Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 24th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $19.14.

Replimune Group Stock Up 11.4 %

REPL stock traded up $1.35 during midday trading on Wednesday, reaching $13.20. 584,264 shares of the company were exchanged, compared to its average volume of 833,930. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. Replimune Group has a 1-year low of $4.92 and a 1-year high of $17.00. The stock’s 50-day simple moving average is $12.16 and its 200 day simple moving average is $11.24. The company has a market cap of $903.01 million, a price-to-earnings ratio of -4.33 and a beta of 1.28.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07. On average, equities analysts forecast that Replimune Group will post -2.91 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Sushil Patel sold 10,000 shares of the business’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the transaction, the chief executive officer now owns 202,014 shares of the company’s stock, valued at approximately $2,509,013.88. The trade was a 4.72 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Konstantinos Xynos sold 7,246 shares of the business’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the transaction, the insider now directly owns 109,885 shares of the company’s stock, valued at $1,184,560.30. The trade was a 6.19 % decrease in their position. The disclosure for this sale can be found here. Insiders own 8.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Point72 DIFC Ltd purchased a new stake in Replimune Group in the 2nd quarter valued at about $57,000. Erste Asset Management GmbH purchased a new stake in shares of Replimune Group during the 3rd quarter worth about $133,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Replimune Group by 82.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company’s stock worth $144,000 after purchasing an additional 5,926 shares during the period. BNP Paribas Financial Markets grew its holdings in shares of Replimune Group by 81.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,011 shares of the company’s stock worth $165,000 after purchasing an additional 6,748 shares during the period. Finally, GSA Capital Partners LLP purchased a new stake in shares of Replimune Group during the 3rd quarter worth about $222,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.